Physicians' Academy for Cardiovascular Education

Diabetes & CVD

Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.

Baseline risk of outcomes does not predict the treatment effect of GLP-1 receptor agonist

Nov. 15, 2017 - news

SGLT-2 inhibition reduces mortality and hospitalization for HF in patients with diabetes and PAD

Nov. 15, 2017 - news

hsCRP levels predict CV outcomes in type 2 diabetic patients post-ACS

Nov. 7, 2017 - Hwang YC, et al. - Diabetes Obes Metab. 2017

Cardiovascular protection in type 2 diabetes

Aug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden

Insights from the first trials in epigenetics in human: What is the way forward?

Oct. 20, 2017 - Barcelona, Spain - Stephen Nicholls, MD, Adelaide, Australia - PACE-CME symposium at ESC 2017

Heart failure & Diabetes: Time for a more unified approach

Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017

Brief update on the LEADER cardiovascular outcomes trial

Oct. 15, 2017 - Prof. Neil Poulter, cardiologist, London, UK

Management of CV Risk & T2DM: Implications of novel outcome trials

Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017

The Clinical Unmet need in the patient with Diabetes and ACS

Aug. 26, 2017 - Barcelona, Spain - Kausik Ray, MD Imperial College London United Kingdom - PACE-CME symposium held at ESC 2017

SGLT2 inhibition in cardiology: What a cardiologist needs to know

Aug. 28, 2017 - Barcelona, Spain - Naveed Sattar, MD, Oxford, United Kingdom - PACE-CME symposium held at ESC 2017

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

Molecular mechanisms involved in the beneficial effect of BET inhibition in experimental renal disease

June 5, 2017 - ERA-EDTA, Madrid Spain - Marta Ruiz-Ortega – Fundación Jiménez Díaz, Madrid, Spain

The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?

June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain

UK: Clinical Dialogues: Lipids & Diabetes 2017

July 7, 2017 - Stratford Upon Avon, United Kingdom - Prof Peter Sever

How incretin therapy changes diabetes and prediabetes management

May 22, 2017

Type of glycemic control is more important than tight glycemic control

May 1, 2017 - ESC HF 2017, Paris

Challenges in Heart Failure management: Diabetes and Renal Impairment

May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris

New diabetes drugs and heart failure: What have we learnt?

May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris

New diabetes treatments with CV benefit: A changing role for the cardiologist

Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)

Modifying CV risk by managing diabetes

Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)

HF & Diabetes: SGLT2 inhibition a paradigm shift?

Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

Challenging cardiovascular risk in diabetes: ready for a new approach?

Aug. 29, 2016 - John Deanfield, MD, University College London, United Kingdom

Overview of SGLT-2 inhibitors in T2DM management: current position & future promise

Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, Rome

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

Aug. 28, 2016 - ESC 2016, Rome - Kausik Ray, MD – Imperial College London, United Kingdom - Recorded at PACE-CME symposium at ESC 2016
##SCROLLER_ITEMS_FULL_TITLE##

The effect of treatment with DPP-4 inhibition on renal complications in diabetic patients.

Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##SCROLLER_ITEMS_FULL_TITLE##

A changing treatment paradigm in diabetes

July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)

SGLT2 inhibition in diabetic kidney disease

Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##SCROLLER_ITEMS_FULL_TITLE##

Exciting times in diabetes treatment: new drug class moves beyond glucose reduction

Apr. 23, 2016 - Kuala Lumpur - Naveed Sattar - University of Glasgow, United Kingdom

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

Baseline risk of outcomes does not predict the treatment effect of GLP-1 receptor agonist

Presented at AHA 2017 Scientific Sessions in Anaheim, CA, USA by Robert J. Mentz (Duke University, Durham, NC, USA)

Nov. 15, 2017 - news

AHA 2017 An analysis of the EXSCEL trial examined whether risk at baseline predicted the effect of exenatide on mortality and MACE.

SGLT-2 inhibition reduces mortality and hospitalization for HF in patients with diabetes and PAD

Presented at AHA 2017 Scientific Sessions in Anaheim, CA, USA by Subodh Verma (St Michael's Hospital, University of Toronto, Canada)

Nov. 15, 2017 - news

AHA 2017 A sub-analysis of the EMPA-REG OUTCOME examined whether the benefits of empaglifozin are preserved in diabetic patients with and without PAD.

hsCRP levels predict CV outcomes in type 2 diabetic patients post-ACS

Nov. 7, 2017 - Hwang YC, et al. - Diabetes Obes Metab. 2017

In post-ACS type 2 diabetic patients at high CV risk, there is a significant association between baseline hsCRP values and future CV outcomes.

Hyperglycemia can explain cognitive dysfunction in diabetic patients

Nov. 1, 2017 - Geijselaers SLC et al. - Diabetes Care 2017

Differences in cognitive performance between diabetic patients and individuals with normal glucose levels can be explained by hyperglycemia and by BP-related variables, but not by insulin resistance.

Diabetes and microvascular complications predict outcomes in HFpEF

Oct. 31, 2017 - Sandesara PB et al. - Diabetes Care 2017

In the TOPCAT study, diabetes and its microvascular complications carried important prognostic information regarding adverse outcomes in HFpEF patients.

Cardiovascular protection in type 2 diabetes

Aug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden
Prof. Lars Rydén describes two classes of drugs that may protect patients with type 2 diabetes from CV events. Depending on the type of patient, cardiologists can choose  a drug.

Prof. Lars Rydén describes two classes of drugs that may protect patients with type 2 diabetes from CV events. Depending on the type of patient, cardiologists can choose a drug.

Insights from the first trials in epigenetics in human: What is the way forward?

Oct. 20, 2017 - Barcelona, Spain - Stephen Nicholls, MD, Adelaide, Australia - PACE-CME symposium at ESC 2017
Lecture by Prof Stephen Nicholls held at symposium on BET Inhibition: Managing high risk diabetes patient with cardiovascular disease: What works, and what else can we do?

This lecture was part of a CME accredited symposium: 'Managing Diabetes & CVD: Is epigenetics a new way forward?' held at ESC 2017 in Barcelona on August 26, 2017

Heart failure & Diabetes: Time for a more unified approach

Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017
PACE-CME symposium held at ESC 2017 - Heart failure & Diabetes: Time for a more unified approach

This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017

BET inhibition may lower CV events in high risk CVD patients, suggests hypothesis-generating analysis

Oct. 18, 2017 - Nicholls SJ et al. - Am J Cardiovasc Drugs. 2017

Pooled analysis of phase II studies evaluating apabetalone suggest that this epigenetic therapeutic may yield clinical benefit for CVD patients with low HDL-C, diabetes, and elevated hsCRP levels.

Potent P2Y12 receptor inhibitor shows stronger antithrombotic effect in T2DM patients with CVD

Oct. 17, 2017 - Zafar MU, et al. - Thromb Haemost 2017

A randomized, cross-over study showed a stronger antiplatelet effect and a faster and more potent antithrombotic effect with ticagrelor than with clopidogrel in T2DM patients with stable CVD.

Brief update on the LEADER cardiovascular outcomes trial

Oct. 15, 2017 - Prof. Neil Poulter, cardiologist, London, UK
Prof. Neil Poulter gives a brief overview of the design and results of the LEADER CV outcomes trial with the GLP-1 agonist liraglutide.

Prof. Neil Poulter gives a brief overview of the design and results of the LEADER CV outcomes trial with the GLP-1 agonist liraglutide.

Management of CV Risk & T2DM: Implications of novel outcome trials

Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017

This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017